论文部分内容阅读
目的研究醛糖还原酶(AR)、一氧化氮(NO)与糖尿病膀胱病(DCP)的关系,探讨醛糖还原酶抑制剂(ARIs)依帕司他对DCP的治疗作用。方法雄性SD大鼠60只分三组:正常组、糖尿病组和治疗组。测定膀胱组织AR活性,NO含量及一氧化氮合酶(NOS)活性。结果与正常组相比,糖尿病组膀胱组织内AR活性、NO含量和NOS活性升高(P<0.01),治疗组AR活性、NO含量和NOS活性均低于糖尿病组(P<0.05)。结论依帕司他通过抑制AR活性,调节NO含量变化及NOS活性,减轻氧化应激反应,改善膀胱组织的功能。
Objective To investigate the relationship between aldose reductase (AR), nitric oxide (NO) and diabetic bladder disease (DCP), and to investigate the therapeutic effect of alprasegrass on plasma DCP in patients with aldose reductase inhibitors (ARIs). Methods Sixty male Sprague-Dawley rats were divided into three groups: normal group, diabetic group and treatment group. AR activity, NO content and nitric oxide synthase (NOS) activity in bladder tissue were determined. Results Compared with normal group, AR activity, NO content and NOS activity in bladder tissue of diabetic group increased (P <0.01). AR activity, NO content and NOS activity in diabetic group were lower than those in diabetic group (P <0.05). Conclusion Epalrestat can inhibit the activity of AR, regulate the content of NO and the activity of NOS, reduce the oxidative stress reaction and improve the function of bladder tissue.